Drugs / NKTR-255
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05676749 | Feb 2024 → Dec 2025 | non-small cell lung carcinoma | AbelZeta Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05359211 | Dec 2022 → Sep 2025 overdue | primary mediastinal large B-cell lymphoma | Fred Hutchinson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04136756 | Oct 2019 → Apr 2023 | non-Hodgkin lymphoma, plasma cell myeloma | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03233854 | Sep 2017 → Jun 2023 overdue | B-cell acute lymphoblastic leukemia | Stanford University | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04616196 | Oct 2020 → Mar 2023 | colorectal cancer, head and neck squamous cell carcinoma | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05632809 | Jan 2023 → Dec 2027 expected | lung cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05327530 | Aug 2022 → Jun 2025 overdue | urothelial carcinoma | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05664217 | Dec 2022 → May 2024 | diffuse large B-cell lymphoma | Nektar Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKTR-255 | “Participants will receive NKTR-255 intravenous infusion” NCT05327530 ↗ |
| Action | Activate | “NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer.” NCT03233854 ↗ |
| Modality | Protein / enzyme biologic | “novel recombinant polymer-conjugated IL15 receptor agonist (NKTR-255)” PMID 38968138 ↗ Oct 2024 |
| Route | Intravenous | “NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability” NCT04136756 ↗ |